NZ598078A - Treatment of brain metastases with macitentan in combination with paclitacel and/or temozolomide and/or radiotherapy - Google Patents

Treatment of brain metastases with macitentan in combination with paclitacel and/or temozolomide and/or radiotherapy

Info

Publication number
NZ598078A
NZ598078A NZ598078A NZ59807810A NZ598078A NZ 598078 A NZ598078 A NZ 598078A NZ 598078 A NZ598078 A NZ 598078A NZ 59807810 A NZ59807810 A NZ 59807810A NZ 598078 A NZ598078 A NZ 598078A
Authority
NZ
New Zealand
Prior art keywords
temozolomide
paclitaxel
radiotherapy
macitentan
treatment
Prior art date
Application number
NZ598078A
Other languages
English (en)
Inventor
Isaiah J Fidler
Sun-Jin Kim
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ598078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of NZ598078A publication Critical patent/NZ598078A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
NZ598078A 2009-08-10 2010-08-09 Treatment of brain metastases with macitentan in combination with paclitacel and/or temozolomide and/or radiotherapy NZ598078A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23268709P 2009-08-10 2009-08-10
PCT/US2010/044832 WO2011019630A2 (en) 2009-08-10 2010-08-09 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors

Publications (1)

Publication Number Publication Date
NZ598078A true NZ598078A (en) 2013-07-26

Family

ID=42938154

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598078A NZ598078A (en) 2009-08-10 2010-08-09 Treatment of brain metastases with macitentan in combination with paclitacel and/or temozolomide and/or radiotherapy

Country Status (27)

Country Link
US (2) US8999934B2 (enExample)
EP (1) EP2464218B1 (enExample)
JP (1) JP2013501791A (enExample)
KR (1) KR20120088665A (enExample)
CN (1) CN102510719B (enExample)
AU (1) AU2010282744B2 (enExample)
BR (1) BR112012003103A2 (enExample)
CA (1) CA2770397A1 (enExample)
CL (1) CL2012000333A1 (enExample)
DK (1) DK2464218T3 (enExample)
EA (1) EA023864B1 (enExample)
ES (1) ES2543280T3 (enExample)
HR (1) HRP20150890T1 (enExample)
HU (1) HUE026005T2 (enExample)
IL (1) IL217915A0 (enExample)
IN (1) IN2012DN01261A (enExample)
MA (1) MA33571B1 (enExample)
MX (1) MX2012001562A (enExample)
NZ (1) NZ598078A (enExample)
PL (1) PL2464218T3 (enExample)
PT (1) PT2464218E (enExample)
SG (1) SG178828A1 (enExample)
SI (1) SI2464218T1 (enExample)
TN (1) TN2012000054A1 (enExample)
TW (1) TWI483938B (enExample)
WO (1) WO2011019630A2 (enExample)
ZA (1) ZA201200980B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012213036A1 (en) * 2011-02-04 2013-09-19 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme
WO2012177624A2 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
SG11201707128TA (en) * 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
JP6903055B2 (ja) 2015-08-03 2021-07-14 イーエヌビー・セラピューティクス・インク Ｅｔｂｒ活性化に関連した癌を治療するための組成物及び方法
JP6996728B2 (ja) * 2016-01-07 2022-01-17 学校法人自治医科大学 グルコーストランスポーター１発現用アデノ随伴ウイルスベクター
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
WO2017209272A1 (ja) * 2016-06-03 2017-12-07 国立大学法人東京大学 がん転移阻害剤
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20190129046A (ko) 2017-02-15 2019-11-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 Nk 세포를 활성화시키기 위한 조성물 및 방법
JP7539151B2 (ja) 2018-01-12 2024-08-23 イーエヌビー・セラピューティクス・インク Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN109232546B (zh) 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
EP3974421B1 (en) 2019-05-22 2024-09-11 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of pyrimidine sulfonamide compound and preparation method therefor
CN112062857B (zh) * 2019-06-10 2024-08-09 鸿运华宁（杭州）生物医药有限公司 Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
KR102951752B1 (ko) * 2019-09-25 2026-04-14 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 안와전두 피질에 대한 시상 입력은 gaba 및 불확대에 의해 매개된 광범한 뇌, 주파수-의존적 억제를 유도한다
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227984B8 (en) 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
PL2254570T3 (pl) 2008-02-20 2014-05-30 Actelion Pharmaceuticals Ltd Połączenie zawierające paklitaksel do leczenia raka jajnika
AU2012213036A1 (en) 2011-02-04 2013-09-19 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme

Also Published As

Publication number Publication date
PT2464218E (pt) 2015-09-16
TWI483938B (zh) 2015-05-11
US8999934B2 (en) 2015-04-07
CN102510719A (zh) 2012-06-20
SG178828A1 (en) 2012-04-27
CL2012000333A1 (es) 2013-01-25
TN2012000054A1 (en) 2013-09-19
CA2770397A1 (en) 2011-02-17
AU2010282744B2 (en) 2014-08-28
EA201270264A1 (ru) 2013-02-28
EP2464218A2 (en) 2012-06-20
TW201109315A (en) 2011-03-16
EA023864B1 (ru) 2016-07-29
HUE026005T2 (en) 2016-04-28
US20120144510A1 (en) 2012-06-07
MX2012001562A (es) 2013-01-29
KR20120088665A (ko) 2012-08-08
ES2543280T3 (es) 2015-08-17
HK1171336A1 (en) 2013-03-28
IL217915A0 (en) 2012-03-29
JP2013501791A (ja) 2013-01-17
WO2011019630A2 (en) 2011-02-17
DK2464218T3 (en) 2015-07-20
CN102510719B (zh) 2015-07-22
US20150352113A1 (en) 2015-12-10
EP2464218B1 (en) 2015-05-27
BR112012003103A2 (pt) 2016-04-19
WO2011019630A3 (en) 2011-06-03
SI2464218T1 (sl) 2015-10-30
IN2012DN01261A (enExample) 2015-05-15
MA33571B1 (fr) 2012-09-01
PL2464218T3 (pl) 2015-12-31
ZA201200980B (en) 2012-10-31
HRP20150890T1 (hr) 2015-09-25
AU2010282744A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
NZ598078A (en) Treatment of brain metastases with macitentan in combination with paclitacel and/or temozolomide and/or radiotherapy
NZ588913A (en) Liver cancer drug
MX350788B (es) Compuestos de carbamato y preparación y uso de los mismos.
PH12013502090A1 (en) 1,3 oxazines as bace1 and/or bace2 inhibitors
PH12013502316A1 (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
WO2004078747A8 (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
IN2012DN01233A (enExample)
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
GEP20156389B (en) Oxazolidin-2-one compounds and their usage as pi3ks inhibitors
MX2009001062A (es) Agonistas de ep2.
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
MY162146A (en) Pharmaceutical composition
TW200833670A (en) Novel compounds 569
MX354173B (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
WO2012168885A9 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
NZ700752A (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel
MX2014013839A (es) 5-amino[1,4]tiazinas como inhibidores de beta-secretasa 1 (bace 1).

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 AUG 2017 BY COMPUTER PACKAGES INC

Effective date: 20140828

LAPS Patent lapsed